Alcobra Ltd. (NASDAQ:ADHD)’s share price dropped 15.7% during trading on Tuesday . The company traded as low as $3.86 and last traded at $4.46, with a volume of 563,980 shares traded. The stock had previously closed at $5.29.

ADHD has been the subject of a number of research analyst reports. Jefferies Group reiterated a “buy” rating on shares of Alcobra in a report on Thursday, August 25th. Cantor Fitzgerald initiated coverage on shares of Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price target for the company. Barclays PLC initiated coverage on shares of Alcobra in a report on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price target for the company. Canaccord Genuity initiated coverage on shares of Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating for the company. Finally, Roth Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Alcobra currently has a consensus rating of “Buy” and a consensus price target of $11.13.

The firm’s market capitalization is $140.84 million. The firm’s 50-day moving average is $4.66 and its 200-day moving average is $4.55.

Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Analysts anticipate that Alcobra Ltd. will post ($0.97) earnings per share for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.